<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The ecto-<z:chebi fb="0" ids="17326">nucleoside triphosphate</z:chebi> diphosphohydrolase CD39 represents a promising antithrombotic therapeutic </plain></SENT>
<SENT sid="1" pm="."><plain>It degrades <z:chebi fb="3" ids="16335">adenosine</z:chebi> 5'-<z:chebi fb="2" ids="18361">diphosphate</z:chebi> (<z:chebi fb="13" ids="16761">ADP</z:chebi>), a main platelet activating/recruiting agent </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that delayed enrichment of CD39 on developing <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> will allow for a low and safe systemic concentration and thus avoid <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>We use a single-chain antibody (scFv, specific for activated GPIIb/IIIa) for targeting CD39 </plain></SENT>
<SENT sid="4" pm="."><plain>This should allow delayed enrichment on growing <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> but not on the initial sealing layer of platelets, which do not yet express activated GPIIb/IIIa </plain></SENT>
<SENT sid="5" pm="."><plain>CD39 was recombinantly fused to an activated GPIIb/IIIa-specific scFv (targ-CD39) and a nonfunctional scFv (non-targ-CD39) </plain></SENT>
<SENT sid="6" pm="."><plain>Targ-CD39 was more effective at preventing <z:chebi fb="13" ids="16761">ADP</z:chebi>-induced platelet activation than non-targ-CD39 </plain></SENT>
<SENT sid="7" pm="."><plain>In a mouse carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> model, non-targ-CD39, although protective against vessel occlusion, was associated with significant <z:mp ids='MP_0001914'>bleeding</z:mp> on tail transection </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, targ-CD39 concentrated at the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> site; hence, a dose âˆ¼10 times less of CD39 prevented vessel occlusion to a similar extent as high-dose non-targ-CD39, without <z:hpo ids='HP_0003010'>prolonged bleeding time</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>An equimolar dose of non-targ-CD39 at this low concentration was ineffective at preventing vessel occlusion </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, delayed targeting of CD39 via scFv to activated platelets provides strong antithrombotic potency and yet prevents <z:mp ids='MP_0001914'>bleeding</z:mp> and thereby promotes CD39 toward clinical use </plain></SENT>
</text></document>